Stock futures pointed to the downside Tuesday on uncertainty over how much escalating trade tensions and President Donald Trump’s tariff policies might affect global growth.
These stocks were poised to make moves Tuesday:
Super Micro Computer was down 4.2% in premarket trading. The maker of servers for artificial intelligence has until Tuesday to file its accounts for the year ended June 30, 2024, and fiscal first quarter ended Sept. 30, 2024, or risk being delisted by the Nasdaq stock exchange. The company had said earlier this month it was working “diligently” to meet the deadline.
Shares of Palantir were falling 2.7% in premarket trading after the the data analytics company fell nearly 11% on Tuesday, the stock’s fourth consecutive down day. Palantir has declined more than 27% over the four sessions. A worry for investors has been whether cuts to U.S. defense spending could affect Palantir’s earnings. The company has several military contracts for the use of its artificial-intelligence technology. Palantir shares remain up 20% for the year.
Nvidia was down 1.3% in premarket trading after a report from Bloomberg said some officials in the Trump administration aimed to place further restrictions on the type of Nvidia chips that can be exported to China without a license. Nvidia, the leading maker of AI chips, is expected by analysts to report adjusted fourth-quarter earnings of 85 cents a share on revenue of $38.1 billion, up from $22.1 billion a year earlier. The report from Nvidia is scheduled for after the closing bell Wednesday. The stock fell 3.1% on Monday and has declined 3% in 2025.
Zoom declined 3.1% after the videoconferencing company issued adisappointing fiscal first-quarter outlook, saying it expects first-quarter revenue of between $1.16 billion and $1.17 billion, missing analysts’ consensus of $1.18 billion. Full-year revenue was forecast at between $4.79 billion and $4.8 billion, missing Wall Street expectations of $4.81 billion.
Fourth-quarter revenue at Hims & Hers Health jumped to $481.1 million from $246.6 million a year earlier, getting a boost from demand for the telehealth-consultation platform’s weight-loss offerings. The company saidrevenue for the year surged 69%to $1.48 billion. Revenue excluding the company’s GLP-1 treatment increased 43% to $1.2 billion in 2024. For the first quarter of 2025, Hims projected revenue of $520 million to $540 million, and adjusted operating earnings of $55 million to $65 million. The stock, however, was down 19% in premarket trading, extending losses from last week after the Food and Drug Administration determined that a shortage of popular weight-loss drugs Wegovy and Ozempichad been resolved.
Coinbase fell 6%, Strategy dropped 7% as the crypto-related stocks followed Bitcoin lower. The world’s largest cryptocurrencyhas declined 7.3% over the past 24 hours to $88,000.
Tempus AI, the health technology company, posted a fourth-quarter loss of $13 million, narrower than its year-earlier loss of $50.5 million. On an adjusted basis, the loss in the period was 18 cents a share. Revenue in the quarter rose 36% to $200.7 million but came up short of forecasts of $203.1 million. The company said it anticipates revenue in 2025 of $1.24 billion, up from $693.4 million in 2024. Shares fell 17%.
Cleveland-Cliffs reported a fourth-quarter adjusted loss of 68 cents a share, wider than Wall Street estimates that called for a loss of 61 cents. Revenue fell 15% from a year earlier to $4.33 billion and came up short of expectations of $4.43 billion. The stock declined 3.3%.
Earnings reports are expected Tuesday from Home Depot, Intuit, Workday, Keurig Dr Pepper, Keysight Technologies, First Solar, Sempra, and Cava Group.
Shares of Home Depot fell 1.2%. The largest home-improvement retailer is scheduled to reportfourth-quarter earningsbefore Wall Street opens Tuesday. Analysts see Home Depot posting a profit in the period of $3.04 a share on sales of $39.2 billion. Estimates also call for Home Depot’s same-store sales to fall by 1.5% year over year.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。